New drug aims to save insulin cells in type 1 diabetes
NCT ID NCT06812988
Summary
This study is testing whether an experimental drug called brivekimig can help protect the body's remaining insulin-producing cells in people recently diagnosed with type 1 diabetes. The goal is to see if the drug can slow the disease's progression and reduce the amount of insulin patients need. About 84 adolescents and adults will receive either the drug or a placebo for one year, followed by safety monitoring.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Advanced Research Institute - Odgen- Site Number : 8400007
Ogden, Utah, 84405, United States
-
Atlanta Diabetes Associates- Site Number : 8400006
Atlanta, Georgia, 30318, United States
-
Centro de Diabetes Curitiba- Site Number : 0760005
Curitiba, Paraná, 80810-040, Brazil
-
Centro de Pesquisas Clínicas - São Paulo- Site Number : 0760002
São Paulo, 01228-200, Brazil
-
IACT Health - Columbus - Talbotton Road- Site Number : 8400012
Columbus, Georgia, 31904, United States
-
Investigational Site Number : 0320001
Buenos Aires, 1119, Argentina
-
Investigational Site Number : 0320002
Buenos Aires, 1178, Argentina
-
Investigational Site Number : 0320003
Salta, 4400, Argentina
-
Investigational Site Number : 0320004
Buenos Aires, 1419, Argentina
-
Investigational Site Number : 0320005
Buenos Aires, 1180, Argentina
-
Investigational Site Number : 0360001
Parkville, Victoria, 3050, Australia
-
Investigational Site Number : 0360002
Brisbane, Queensland, 4029, Australia
-
Investigational Site Number : 0360003
Saint Leonards, New South Wales, 2065, Australia
-
Investigational Site Number : 1240001
Vancouver, British Columbia, V5Y 3W2, Canada
-
Investigational Site Number : 1240006
Surrey, British Columbia, V3T 2V6, Canada
-
Investigational Site Number : 1520001
Santiago, Reg Metropolitana de Santiago, 7500505, Chile
-
Investigational Site Number : 1520003
Providencia, Reg Metropolitana de Santiago, 7500000, Chile
-
Investigational Site Number : 1520004
Concepción, Región del Biobío, 4070566, Chile
-
Investigational Site Number : 3760001
Jerusalem, 9112001, Israel
-
Investigational Site Number : 3760002
Ramat Gan, 5262100, Israel
-
Investigational Site Number : 3760003
Kefar Sava, 4428164, Israel
-
Investigational Site Number : 6820002
Riyadh, 12713, Saudi Arabia
-
Profound Research - MHP - TriAtria- Site Number : 8400015
Farmington Hills, Michigan, 48334, United States
-
Tekton Research - McKinney- Site Number : 8400017
McKinney, Texas, 75069, United States
Conditions
Explore the condition pages connected to this study.